FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
Source link
The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
Source link
